Völcker M, Peters S, Inhoffen W, Ziemssen F
Augenklinik, Eberhard-Karls-Universität, Schleichstrasse 12, 72076 Tübingen.
Ophthalmologe. 2006 Jun;103(6):476-83. doi: 10.1007/s00347-006-1356-1.
VEGF is more potent than histamine by a factor of 50,000 for inducing increased vessel permeability. Already in the first few minutes, hydraulic conductivity and diffusive permeability are significantly increased, followed by a longer-lasting, marked leakage over 20 h. Specific inhibition of the angiogenic, vasoactive, and permeability-inducing protein VEGF is now possible by new drugs, one of which is the first available (off-label) treatment in Germany for routine clinical use (Avastin). Retinal edema is composed of increased outflow of water and low molecular substances in the interstitial environment and is an important determinate of functional development in different ocular diseases. First experiences with the anti-hyperpermeability effect show early response and high potential in pathologic leakage. Future examinations have to assess when a permanent benefit can be achieved in respect to the other antiproliferative capabilities of the drug.
血管内皮生长因子(VEGF)在诱导血管通透性增加方面比组胺强50000倍。在最初几分钟内,水力传导率和扩散通透性就会显著增加,随后在20小时内会出现持续时间更长、明显的渗漏。新型药物现已能够特异性抑制血管生成、血管活性和诱导通透性的蛋白质VEGF,其中一种药物是德国首个可用于常规临床治疗(阿瓦斯汀)的非标签药物。视网膜水肿是由间质环境中水分和低分子物质流出增加所构成,并且是不同眼部疾病功能发展的一个重要决定因素。抗高通透性作用的初步经验显示出对病理性渗漏的早期反应和巨大潜力。未来的研究必须评估何时能在该药物的其他抗增殖能力方面实现持久益处。